Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1977 Dec 1;146(6):1791–1803. doi: 10.1084/jem.146.6.1791

Inhibition of lymphocyte proliferation stimulated by lectins and allogeneic cells by normal plasma lipoproteins

PMCID: PMC2181900  PMID: 200701

Abstract

Lipoproteins, isolated by sequential flotation at densities 1.006, 1.019, 1.063, and 1.21, were examined for their ability to inhibit human lymphocytes stimulated by allogeneic cells and by lectins (phytohemagglutinin-P and concanavalin A). All the classes of normal plasma lipoproteins inhibited lymphoproliferation when peripheral blood lymphocytes were cultured in autologous, heterologous, or lipoprotein- deficient plasma (d greater than 1.21). The rank order of inhibitory potency was intermediate density lipoprotein (IDL) greater than very low density lipoproteins (VLDL) greater than low density lipoproteins (LDL) greater than high density lipoproteins (HDL), regardless of the mode of stimulation. The concentrations of IDL, VLDL, and LDL required for complete inhibition of stimulated lymphoproliferation were considerably below the levels of each of these lipoproteins normally found in human plasma. In addition, the concentration of HDL required for 50-90% inhibition was in the range of HDL levels normally found in human plasma. Moreover, at relatively higher concentrations, lipoproteins suppressed the incorporation of [3H]thymidine into DNA below the levels seen with reseting, unstimulated lymphocytes. The results suggest that circulating lymphocytes may normally be highly suppressed by the combined effects of all the endogenous lipoproteins and that the lipoproteins may play important roles in vivo in modulating lymphocyte functions and responses.

Full Text

The Full Text of this article is available as a PDF (899.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benson M. D., Aldo-Benson M. A., Shirahama T., Borel Y., Cohen A. S. Suppression of in vitro antibody response by a serum factor (SAA) in experimentally induced amyloidosis. J Exp Med. 1975 Jul 1;142(1):236–241. doi: 10.1084/jem.142.1.236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Berken A., Benacerraf B. Depression of reticuloendothelial system phagocytic function by ingested lipids. Proc Soc Exp Biol Med. 1968 Jul;128(3):793–795. doi: 10.3181/00379727-128-33124. [DOI] [PubMed] [Google Scholar]
  3. Brown M. S., Goldstein J. L. Receptor-mediated control of cholesterol metabolism. Science. 1976 Jan 16;191(4223):150–154. doi: 10.1126/science.174194. [DOI] [PubMed] [Google Scholar]
  4. Burstein M., Scholnick H. R. Lipoprotein-polyanion-metal interactions. Adv Lipid Res. 1973;11(0):67–108. [PubMed] [Google Scholar]
  5. Burstein M., Scholnick H. R., Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res. 1970 Nov;11(6):583–595. [PubMed] [Google Scholar]
  6. Chisari F. V., Edgington T. S. Lymphocyte E rosette inhibitory factor: a regulatory serum lipoprotein. J Exp Med. 1975 Nov 1;142(5):1092–1107. doi: 10.1084/jem.142.5.1092. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cooperband S. R., Nimberg R., Schmid K., Mannick J. A. Humoral immunosuppressive factors. Transplant Proc. 1976 Jun;8(2):225–242. [PubMed] [Google Scholar]
  8. Curtiss L. K., DeHeer D. H., Edgington T. S. In vivo suppression of the primary immune response by a species of low density serum lipoprotein. J Immunol. 1977 Feb;118(2):648–652. [PubMed] [Google Scholar]
  9. Curtiss L. K., Edgington T. S. Regulatory serum lipoproteins: regulation of lymphocyte stimulation by a species of low density lipoprotein. J Immunol. 1976 May;116(5):1452–1458. [PubMed] [Google Scholar]
  10. Eisenberg S., Levy R. I. Lipoprotein metabolism. Adv Lipid Res. 1975;13:1–89. [PubMed] [Google Scholar]
  11. Fredrickson D. S., Levy R. I., Lees R. S. Fat transport in lipoproteins--an integrated approach to mechanisms and disorders. N Engl J Med. 1967 Jan 26;276(4):215–contd. doi: 10.1056/NEJM196701262760406. [DOI] [PubMed] [Google Scholar]
  12. Girmann G., Pees H., Schwarze G., Scheurlen P. G. Immunosuppression by micromolecular fibrinogen degradation products in cancer. Nature. 1976 Feb 5;259(5542):399–401. doi: 10.1038/259399a0. [DOI] [PubMed] [Google Scholar]
  13. HAVEL R. J., EDER H. A., BRAGDON J. H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955 Sep;34(9):1345–1353. doi: 10.1172/JCI103182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Harmony J. A., Cordes E. H. Interaction of human plasma low density lipoprotein with concanavalin A and with ricin. J Biol Chem. 1975 Nov 25;250(22):8614–8617. [PubMed] [Google Scholar]
  15. Harrison M. R., Thurman G. B., Thomas G. M. A simple and versatile harvesting device for processing radioactive label incorporated into and-or released from cells in microculture. J Immunol Methods. 1974 Jan;3(1):11–16. doi: 10.1016/0022-1759(74)90027-1. [DOI] [PubMed] [Google Scholar]
  16. Ho Y. K., Brown M. S., Kayden H. J., Goldstein J. L. Binding, internalization, and hydrolysis of low density lipoprotein in long-term lymphoid cell lines from a normal subject and a patient with homozygous familial hypercholesterolemia. J Exp Med. 1976 Aug 1;144(2):444–455. doi: 10.1084/jem.144.2.444. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ho Y. K., Brown S., Bilheimer D. W., Goldstein J. L. Regulation of low density lipoprotein receptor activity in freshly isolated human lymphocytes. J Clin Invest. 1976 Dec;58(6):1465–1474. doi: 10.1172/JCI108603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Jackson R. L., Morrisett J. D., Gotto A. M., Jr Lipoprotein structure and metabolism. Physiol Rev. 1976 Apr;56(2):259–316. doi: 10.1152/physrev.1976.56.2.259. [DOI] [PubMed] [Google Scholar]
  19. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  20. Leffert H. L., Weinstein D. B. Growth control of differentiated fetal rat hepatocytes in primary monolayer culture. IX. Specific inhibition of DNA synthesis initiation by very low density lipoprotein and possible significance to the problem of liver regeneration. J Cell Biol. 1976 Jul;70(1):20–32. doi: 10.1083/jcb.70.1.20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. MOWBRAY J. F. Ability of large doses of an alpha-2 plasma protein fraction to inhibit antibody production. Immunology. 1963 May;6:217–225. [PMC free article] [PubMed] [Google Scholar]
  22. McConathy W. J., Alaupovic P. Studies on the interaction of concanavalin A with major density classes of human plasma lipoproteins. Evidence for the specific binding of lipoprotein B in its associated and free forms. FEBS Lett. 1974 Apr 15;41(1):174–178. doi: 10.1016/0014-5793(74)80981-6. [DOI] [PubMed] [Google Scholar]
  23. Mihas A. A., Gibson R. G., Hirschowitz B. I. Suppression of lymphocyte transformation by 16, (16) dimethyl prostaglandin E2 and unsaturated fatty acids. Proc Soc Exp Biol Med. 1975 Sep;149(4):1026–1028. doi: 10.3181/00379727-149-38949. [DOI] [PubMed] [Google Scholar]
  24. Mortensen R. F., Osmand A. P., Gewurz H. Effects on C-reactive protein on the lymphoid system. I. Binding to thymus-dependent lymphocytes and alteration of their functions. J Exp Med. 1975 Apr 1;141(4):821–839. [PMC free article] [PubMed] [Google Scholar]
  25. Murgita R. A., Tomasi T. B., Jr Suppression of the immune response by alpha-fetoprotein on the primary and secondary antibody response. J Exp Med. 1975 Feb 1;141(2):269–286. doi: 10.1084/jem.141.2.269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Noble R. P., Campbell F. M. Improved accuracy in automated fluorometric determination of plasma triglycerides. Clin Chem. 1970 Mar;16(3):166–170. [PubMed] [Google Scholar]
  27. Occhino J. C., Glasgow A. H., Cooperband S. R., Mannick J. A., Schmid K. Isolation of an immunosuppressive peptide fraction from human plasma. J Immunol. 1973 Mar;110(3):685–694. [PubMed] [Google Scholar]
  28. Powell A. E., Leon M. A. Reversible interaction of human lymphocytes with the mitogen concanavalin A. Exp Cell Res. 1970 Oct;62(2):315–325. doi: 10.1016/0014-4827(70)90560-4. [DOI] [PubMed] [Google Scholar]
  29. Salem N. B., Morse J. H. Lymphocyte response to mitogens in progressive systemic sclerosis. Arthritis Rheum. 1976 Sep-Oct;19(5):875–882. doi: 10.1002/art.1780190507. [DOI] [PubMed] [Google Scholar]
  30. Schaffner W., Weissmann C. A rapid, sensitive, and specific method for the determination of protein in dilute solution. Anal Biochem. 1973 Dec;56(2):502–514. doi: 10.1016/0003-2697(73)90217-0. [DOI] [PubMed] [Google Scholar]
  31. Shinitzky M., Inbar M. Difference in microviscosity induced by different cholesterol levels in the surface membrane lipid layer of normal lymphocytes and malignant lymphoma cells. J Mol Biol. 1974 Jan 5;85(4):603–615. doi: 10.1016/0022-2836(74)90318-0. [DOI] [PubMed] [Google Scholar]
  32. Toyoshima S., Osawa T. Cholesterol inhibition of the temporary increase of membrane fluidity of lymphocytes induced by mitogenic lectins. Exp Cell Res. 1976 Oct 15;102(2):438–441. doi: 10.1016/0014-4827(76)90066-5. [DOI] [PubMed] [Google Scholar]
  33. Waddell C. C., Taunton O. D., Twomey J. J. Inhibition of lymphoproliferation by hyperlipoproteinemic plasma. J Clin Invest. 1976 Oct;58(4):950–954. doi: 10.1172/JCI108548. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES